Advertisement
Research ArticleENDOCRINE AND DIABETES

Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose Level

Kenji Katsuno, Yoshikazu Fujimori, Yukiko Takemura, Masahiro Hiratochi, Fumiaki Itoh, Yoshimitsu Komatsu, Hideki Fujikura and Masayuki Isaji
Journal of Pharmacology and Experimental Therapeutics January 2007, 320 (1) 323-330; DOI: https://doi.org/10.1124/jpet.106.110296
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleENDOCRINE AND DIABETES

Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose Level

Kenji Katsuno, Yoshikazu Fujimori, Yukiko Takemura, Masahiro Hiratochi, Fumiaki Itoh, Yoshimitsu Komatsu, Hideki Fujikura and Masayuki Isaji
Journal of Pharmacology and Experimental Therapeutics January 1, 2007, 320 (1) 323-330; DOI: https://doi.org/10.1124/jpet.106.110296
Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement